Core Insights - Eddie Pharmaceutical experienced a 5.1% increase in stock price, reaching 17.52 CNY per share, with a trading volume of 196 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 7.372 billion CNY [1] Company Overview - Jiangsu Eddie Pharmaceutical Group Co., Ltd. was established on December 15, 2009, and went public on July 20, 2020. The company focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The main revenue sources include: - HIV new drug (Ainomi tablet) 31.96% - Drug (urokinase injection) 19.16% - Senna leaf granules 13.25% - Ustikin crude product 12.08% - Urokinase crude product 10.81% - Other human-derived protein crude products 4.18% - HIV new drug (Ainovelin tablet) 3.92% - Other drugs 2.76% - HIV diagnostic reagents 0.80% - Bacillus cereus tablets 0.54% - Other (supplement) 0.54% [1] Shareholder Insights - Among the top circulating shareholders of Eddie Pharmaceutical, one fund from GF Fund Management, the GF Value Core Mixed A (010377), entered the top ten in the second quarter, holding 3.931 million shares, which is 0.93% of the circulating shares. The estimated floating profit today is approximately 3.3413 million CNY [2] - The GF Value Core Mixed A fund was established on January 22, 2021, with a current scale of 3.516 billion CNY. Year-to-date returns are 64.01%, ranking 307 out of 8180 in its category; the one-year return is 107.77%, ranking 276 out of 7967; since inception, it has a loss of 3.45% [2]

Core Insights - The company anticipates a 61% growth in its generic drug revenue for the first half of 2025, driven primarily by increased sales of its unique product, Senna Leaf Granules [1] Company Performance - The significant revenue growth in the generic drug segment is attributed to the rising demand for Senna Leaf Granules, which is used for treating constipation and promoting bowel movements [1]